Last reviewed · How we verify
glucose-based peritoneal dialysate
glucose-based peritoneal dialysate is a Peritoneal dialysis solution Small molecule drug developed by Chinese University of Hong Kong. It is currently FDA-approved for End-stage renal disease requiring peritoneal dialysis.
Glucose-based peritoneal dialysate facilitates removal of uremic waste products and excess fluid from the blood across the peritoneal membrane during peritoneal dialysis.
Glucose-based peritoneal dialysate facilitates removal of uremic waste products and excess fluid from the blood across the peritoneal membrane during peritoneal dialysis. Used for End-stage renal disease requiring peritoneal dialysis.
At a glance
| Generic name | glucose-based peritoneal dialysate |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Drug class | Peritoneal dialysis solution |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Mechanism of action
Peritoneal dialysate containing glucose creates an osmotic gradient across the peritoneal membrane, drawing excess water and small solute molecules from the bloodstream into the dialysate fluid. The glucose concentration in the solution determines the osmotic strength and ultrafiltration rate. This allows patients with kidney failure to perform peritoneal dialysis at home or in clinical settings without requiring hemodialysis machines.
Approved indications
- End-stage renal disease requiring peritoneal dialysis
Common side effects
- Peritonitis
- Hyperglycemia
- Abdominal discomfort
- Catheter-related infections
Key clinical trials
- Analysis of the Influence of Dialysis Fluid Composition on Vascular Calcification in Patients With Chronic Kidney Disease Undergoing Hemodialysis (NA)
- Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy
- Incremental PD With Single Icodextrin Exchange (NA)
- Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients (PHASE1)
- Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution (PHASE1)
- Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD (PHASE2)
- The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
- Direct Peritoneal Resuscitation in Gastroschisis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glucose-based peritoneal dialysate CI brief — competitive landscape report
- glucose-based peritoneal dialysate updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI
Frequently asked questions about glucose-based peritoneal dialysate
What is glucose-based peritoneal dialysate?
How does glucose-based peritoneal dialysate work?
What is glucose-based peritoneal dialysate used for?
Who makes glucose-based peritoneal dialysate?
What drug class is glucose-based peritoneal dialysate in?
What development phase is glucose-based peritoneal dialysate in?
What are the side effects of glucose-based peritoneal dialysate?
Related
- Drug class: All Peritoneal dialysis solution drugs
- Manufacturer: Chinese University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Nephrology
- Indication: Drugs for End-stage renal disease requiring peritoneal dialysis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing